Stock AOLS AEOLUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Aeolus Pharmaceuticals, Inc.

Equities

AOLS

US00765G1094

Market Closed - OTC Markets
Other stock markets
 15:44:28 11/04/2024 BST 		5-day change 1st Jan Change
0.000001 USD -99.00% Intraday chart for Aeolus Pharmaceuticals, Inc. -.--% -.--%
2017 Aeolus Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and First Nine Months Ended June 30, 2017 CI
2017 Aeolus Pharmaceuticals, Inc. Announces Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Aeolus Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and First Nine Months Ended June 30, 2017
CI
Aeolus Pharmaceuticals, Inc. Announces Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event
CI
Aeolus Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2017
CI
Aeolus Pharmaceuticals, Inc. Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers
CI
Aeolus Pharmaceuticals Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2016
CI
Aeolus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2016
CI
Aeolus Pharmaceuticals Inc. Announces Unaudited Consolidated Results for the Second Quarter and Six Months Ended March 31, 2016
CI
Aeolus Pharmaceuticals Inc. Announces Removal of FDA Clinical Hold on AEOL 10150
CI
Aeolus Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended December 31, 2015
CI
Aeolus Pharmaceuticals Enters into Definitive Agreements to Raise Gross Proceeds of $6.75 Million in Private Placement Financing
CI
Aeolus Pharmaceuticals Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2015
CI
Aeolus Pharmaceuticals Inc. announced that it has received $6.75 million in funding from BVF Partners LP and other investors.
CI
Aeolus Pharmaceuticals Inc. announced that it has received $1 million in funding from BVF Partners LP.
CI
Aeolus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015
CI
Barda Exercises $3 Million in Additional Contract Funding for Development of Aeol 10150 as Treatment for Acute Radiation Syndrome
CI
Aeolus Pharmaceuticals Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended March 31, 2015
CI
Aeolus Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended December 31, 2014
CI
Aeolus Pharmaceuticals Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2014
CI
Aeolus Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt
CI
Aeolus Pharmaceuticals Inc. Announces Presentation of Efficacy Data for AEOL 10150
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AOLS Stock
  4. News Aeolus Pharmaceuticals, Inc.